Research programme: fast dissolve tablet therapeutics - Samyang

Drug Profile

Research programme: fast dissolve tablet therapeutics - Samyang

Alternative Names: Methylphenidate fast disolve tablet - Samyang; Orally disintegrating tablet therapeutics - Samyang; Risperidone fast disolve tablet - Samyang; Tacrolimus fast disolve tablet - Samyang

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Samyang Biopharmaceuticals Corporation
  • Class Isoxazoles; Lactones; Macrolides; Phenylacetates; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors; Dopamine D2 receptor antagonists; Dopamine release stimulants; Immunosuppressants; Serotonin 2A receptor antagonists; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder; Schizophrenia; Transplant rejection

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in South Korea (PO, Fast dissolve)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in South Korea (PO, Fast dissolve)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Transplant-rejection in South Korea (PO, Fast dissolve)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top